Biotech Values

[gfp927z]

Biomaven, Any thoughts on Polymedix?

They'll be getting the full Phase 2 antibiotic data soon, as well as Phase 2 results for the two heptagonist trials.





>>> PolyMedix's PMX-30063 First in Class Defensin-Mimetic Antibiotic Demonstrates Activity Against Drug-Resistant Bacterial Pathogens


Data Presented at ECCMID 2012 Meeting

Mon, Apr 2, 2012


http://finance.yahoo.com/news/polymedixs-pmx-30063-first-class-110000092.html




RADNOR, Pa., April 2, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX.OB - News), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, announced today that its lead defensin-mimetic antibiotic, PMX-30063, has shown activity against 1,000 worldwide strains of Gram-positive staphylococci and streptococci clinical isolates, including strains resistant to linezolid, daptomycin, and methicillin. The data were presented at the 21st Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in London, United Kingdom. The presentation is available on PolyMedix's website at www.Polymedix.com.

"These important and encouraging data further substantiate the robust antimicrobial activity of PMX-30063 regardless of the existing mechanisms of resistance or geographic source of the isolates," commented Dr. Bozena Korczak, Vice President of Drug Development at PolyMedix. "This is the first time we are presenting to the scientific community PMX-30063's activity against worldwide multi-drug resistant strains of staphylococci and streptococci that are associated with skin and skin structure infections."

PMX-30063 is the first of a new class of antibiotics known as defensin-mimetics. It is a small molecule designed to mimic the activity of human host-defense proteins, the body's natural defense against bacterial infections. PMX-30063, like host-defense proteins, kills bacteria by directly targeting bacterial membranes and disrupting them. Widespread resistance to this mechanism of action has not developed despite being employed by humans and other organisms to fight deadly bacteria for millions of years. PMX-30063 has been successfully tested in three Phase 1 clinical studies and has now completed enrollment in a blinded and controlled Phase 2 trial in patients with Acute Bacterial Skin and Skin Structure Infections caused by Staph aureus bacteria. Data from this study are expected in the first half of 2012.

About PolyMedix, Inc.

PolyMedix is a clinical stage biotechnology company developing first-in-class, small-molecule drugs for the treatment of serious acute care conditions. PolyMedix has a pipeline of innovative infectious disease and cardiovascular product candidates, all of which were internally developed using a proprietary drug discovery platform.

PolyMedix's lead infectious disease compound is PMX-30063, the first drug from a new class of antibiotics, the defensin-mimetics. Defensin-mimetic antibiotics are designed to imitate natural human immunity (host defense proteins). By mimicking the mechanism of action of the host defense proteins, PMX-30063 works completely differently from conventional biochemical antibiotics, and exploits a method of bacterial cell killing that significantly reduces the risk of bacterial resistance. PMX-30063 has completed enrollment in a Phase 2 clinical trial to treat patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Staph aureus bacteria, including methicillin-resistant Staph aureus (MRSA). PolyMedix is also leveraging its antimicrobial expertise with its PolyCides(R), antimicrobial additives to materials to create self-sterilizing products and surfaces.

PolyMedix's lead cardiovascular compound is PMX-60056, which is designed to normalize blood clotting in patients on heparin and low molecular weight heparins (LMWHs) PMX-60056 is currently in a Phase 2 clinical trial in patients undergoing PCI, and in a Phase 1B/2 dose ranging clinical trial with the LMWH enoxaparin.

For more information, please visit our website at www.polymedix.com.


<<<